43 related articles for article (PubMed ID: 23375727)
1. Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850).
Marchetti C; Giannarelli D; Vizzielli G; Ferrandina G; Tortorella L; Fanfani F; Costantini B; Pasciuto T; Scambia G; Fagotti A
BJOG; 2023 Dec; 130(13):1579-1588. PubMed ID: 37334772
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
Reyners AKL; de Munck L; Erdkamp FLG; Smit WM; Hoekman K; Lalisang RI; de Graaf H; Wymenga ANM; Polee M; Hollema H; van Vugt MATM; Schaapveld M; Willemse PHB;
Ann Oncol; 2012 Nov; 23(11):2896-2902. PubMed ID: 22689176
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy.
Liontos M; Andrikopoulou A; Koutsoukos K; Markellos C; Skafida E; Fiste O; Kaparelou M; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
J Ovarian Res; 2021 Nov; 14(1):148. PubMed ID: 34724958
[TBL] [Abstract][Full Text] [Related]
4. Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study.
Filippova OT; Boecking K; Broach V; Gardner GJ; Sonoda Y; Chi DS; Zivanovic O; Long Roche K
Gynecol Oncol; 2024 May; 187():80-84. PubMed ID: 38735143
[TBL] [Abstract][Full Text] [Related]
5. Multifactorial impact on the outcome of interval debulking surgery in patients with advanced epithelial ovarian or peritoneal cancers.
Jiang QX; Jiang YX; Wang X; Luo SJ; Zhou R; Linghu H
Clin Chim Acta; 2019 Aug; 495():148-153. PubMed ID: 30885671
[TBL] [Abstract][Full Text] [Related]
6. Upfront debulking surgery or delayed surgery after neoadjuvant chemotherapy for advanced-stage epithelial ovarian cancer: Comparison of survival from a noncancer center in India.
Shekhar S; Singh P; Vishnoi JR; Goel S; Pareek P; Sharma C; Goyal M; Yadav G; Jhirwal M; Soni S; Misra S
Indian J Cancer; 2023 Aug; ():. PubMed ID: 38090972
[TBL] [Abstract][Full Text] [Related]
7. Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review.
Moufarrij S; Sassine D; Basaran D; Jewell EL
Gynecol Oncol; 2023 Mar; 170():167-171. PubMed ID: 36701837
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with emergency room readmission after elective surgery for ovarian carcinoma.
Salcedo-Hernandez RA; Barquet-Muñoz S; Isla-Ortiz D; Lucero-Serrano F; Lino-Silva LS; de León DC; Cetina-Perez L
BMC Womens Health; 2023 Sep; 23(1):473. PubMed ID: 37667261
[TBL] [Abstract][Full Text] [Related]
9. Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer.
De Bruyn C; Ceusters J; Landolfo C; Baert T; Thirion G; Claes S; Vankerckhoven A; Wouters R; Schols D; Timmerman D; Vergote I; Coosemans A
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885008
[TBL] [Abstract][Full Text] [Related]
10. Impact of preoperative carbohydrate loading on postoperative course and morbidity in debulking surgery for epithelial ovarian cancer.
Toptas T; Ureyen I; Kahraman A; Gokkaya M; Yalcin N; Alci A; Kole MC; Kandemi R S; Goksu M; Akgul N; Dogan S
Exp Ther Med; 2024 May; 27(5):181. PubMed ID: 38515650
[TBL] [Abstract][Full Text] [Related]
11. Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.
Cummings M; Nicolais O; Shahin M
Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35454036
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis.
Lv X; Cui S; Zhang X; Ren C
J Gynecol Oncol; 2020 Mar; 31(2):e12. PubMed ID: 31912670
[TBL] [Abstract][Full Text] [Related]
13. The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies.
Qin M; Jin Y; Ma L; Zhang YY; Pan LY
Oncotarget; 2018 Feb; 9(9):8614-8628. PubMed ID: 29492221
[TBL] [Abstract][Full Text] [Related]
14. Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?
Barber EL; Rossi EC; Gehrig PA
Gynecol Oncol; 2017 Dec; 147(3):607-611. PubMed ID: 28941658
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification and outcomes of women undergoing surgery for ovarian cancer.
Patankar S; Burke WM; Hou JY; Tergas AI; Huang Y; Ananth CV; Neugut AI; Hershman DL; Wright JD
Gynecol Oncol; 2015 Jul; 138(1):62-9. PubMed ID: 25976399
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.
Sato S; Itamochi H
Ther Adv Med Oncol; 2014 Nov; 6(6):293-304. PubMed ID: 25364394
[TBL] [Abstract][Full Text] [Related]
17. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?
Worley MJ; Guseh SH; Rauh-Hain JA; Williams KA; Muto MG; Feltmate CM; Berkowitz RS; Horowitz NS
Gynecol Oncol; 2013 Apr; 129(1):69-73. PubMed ID: 23375727
[TBL] [Abstract][Full Text] [Related]
18. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
